- Home
- NNN vs JAZZ Comparison
NNN vs JAZZ Comparison
Compare NNN & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNN
- JAZZ
- Stock Information
- Founded
- NNN 1984
- JAZZ 2003
- Country
- NNN United States
- JAZZ Ireland
- Employees
- NNN N/A
- JAZZ N/A
- Industry
- NNN Real Estate Investment Trusts
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- NNN Real Estate
- JAZZ Health Care
- Exchange
- NNN Nasdaq
- JAZZ Nasdaq
- Market Cap
- NNN 7.8B
- JAZZ 6.7B
- IPO Year
- NNN N/A
- JAZZ 2007
- Fundamental
- Price
- NNN $42.74
- JAZZ $118.23
- Analyst Decision
- NNN Hold
- JAZZ Strong Buy
- Analyst Count
- NNN 10
- JAZZ 12
- Target Price
- NNN $44.78
- JAZZ $183.00
- AVG Volume (30 Days)
- NNN 1.1M
- JAZZ 636.6K
- Earning Date
- NNN 08-05-2025
- JAZZ 08-04-2025
- Dividend Yield
- NNN 5.42%
- JAZZ N/A
- EPS Growth
- NNN N/A
- JAZZ 49.21
- EPS
- NNN 2.14
- JAZZ 7.51
- Revenue
- NNN $884,713,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- NNN $5.02
- JAZZ $6.00
- Revenue Next Year
- NNN $3.76
- JAZZ $4.85
- P/E Ratio
- NNN $20.01
- JAZZ $15.74
- Revenue Growth
- NNN 5.40
- JAZZ 5.76
- 52 Week Low
- NNN $35.80
- JAZZ $95.49
- 52 Week High
- NNN $49.57
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- NNN 48.23
- JAZZ 65.45
- Support Level
- NNN $42.50
- JAZZ $115.92
- Resistance Level
- NNN $43.50
- JAZZ $119.48
- Average True Range (ATR)
- NNN 0.69
- JAZZ 2.88
- MACD
- NNN -0.10
- JAZZ 0.71
- Stochastic Oscillator
- NNN 23.98
- JAZZ 89.25
About NNN NNN REIT Inc.
NNN REIT Inc is a real estate investment trust that invests in and develops properties throughout the United States. The company generates revenue from leasing properties to tenants, including convenience stores, automotive services, fitness centers, theatres, restaurants, and banks. Rents from convenience stores and restaurants contribute the majority proportion of total revenue. The maximum of the company's properties are located in the South and Southeast of the United States.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.